Trinity Biotech (TRIB) Cash & Equivalents (2009 - 2025)

Trinity Biotech has disclosed Cash & Equivalents across 17 years of filings, most recently posting $5.1 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $5.1 million, down 0.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.1 million (down 0.56% YoY), and the FY2025 annual result was $5.1 million, up 39.2% from the prior year.
• Cash & Equivalents came in at $5.1 million for Q4 2025 at Trinity Biotech, up from $1.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $32.3 million in Q1 2021 to a low of $1.5 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $7.3 million (2022), against an average of $14.8 million.
• Across the five-year window, Cash & Equivalents soared 143.71% in 2021 and plunged 74.65% in 2022, its largest moves.
• Trinity Biotech's Cash & Equivalents stood at $25.9 million in 2021, then sank by 74.61% to $6.6 million in 2022, then tumbled by 43.89% to $3.7 million in 2023, then soared by 39.99% to $5.2 million in 2024, then declined by 0.56% to $5.1 million in 2025.
• The last three Cash & Equivalents figures came in at $5.1 million (Q4 2025), $1.5 million (Q2 2025), and $5.2 million (Q4 2024), per Business Quant data.